8-K12B: Kiniksa Pharmaceuticals Completes Redomiciliation to the United Kingdom

Kiniksa Pharmaceuticals International, plc has successfully completed its redomiciliation from Bermuda to the United Kingdom, becoming the successor issuer.

Summary

• Kiniksa Pharmaceuticals International, plc completed its redomiciliation from Bermuda to the United Kingdom on June 27, 2024.
• The company became the successor issuer to Kiniksa Pharmaceuticals, Ltd. following the effectiveness of a Bermuda court-approved scheme of arrangement.
• Shareholders of Kiniksa Bermuda received equivalent shares in Kiniksa Pharmaceuticals International, plc on a one-for-one basis.
• The Class A Ordinary Shares of the company began trading on Nasdaq under the symbol KNSA on June 28, 2024.
• Certain shareholders received Depositary Receipts representing their ordinary shares due to transfer restrictions.
• The company issued approximately 40,447,538 Class A Ordinary Shares, 1,795,158 Class B Ordinary Shares, 12,781,964 Class A1 Ordinary Shares and 16,057,618 Class B1 Ordinary Shares in connection with the redomiciliation.
• The executive officers and directors of Kiniksa Bermuda immediately prior to the redomiciliation became the executive officers and directors of the company.
• The company assumed the rights and obligations of Kiniksa Bermuda in its equity incentive plans, converting outstanding awards on a one-for-one basis.

Sentiment

Score: 7

Explanation: The document reflects a positive development for the company, with a successful redomiciliation and continuity of operations. However, the issuance of Depositary Receipts and the lack of a trading market for them introduces a minor negative aspect.

Positives

• The redomiciliation was completed successfully and on schedule.
• The company's shares continue to trade on Nasdaq under the same symbol, ensuring continuity for investors.
• Existing management and directors remain in place, providing stability.
• The company has assumed all existing equity incentive plans, ensuring continuity for employees.

Negatives

• Some shareholders received Depositary Receipts instead of direct shares due to transfer restrictions, which may limit their trading flexibility.
• The Depositary Receipts are not registered or listed on any stock exchange and no trading market is expected to develop.

Risks

• The Depositary Receipts are not registered or listed on any stock exchange, and no trading market is expected to develop, which may limit liquidity for some shareholders.
• The Depositary Receipts arrangement was established because, as a result of restrictions on transfer on certain of the Company Shares concerned, such Company Shares could not be issued directly into The Depository Trust Company (DTC) at the time of the Redomiciliation.

Future Outlook

The company will continue to operate as Kiniksa Pharmaceuticals International, plc, with its Class A Ordinary Shares trading on Nasdaq under the symbol KNSA.

Management Comments

• Sanj K. Patel will serve as Chief Executive Officer and Chairman of the Board of Directors of the Company.
• Mark Ragosa will serve as Chief Financial Officer.
• Michael Megna will serve as Group Vice President of Finance and Chief Accounting Officer.
• Eben Tessari will serve as Senior Vice President, Chief Operating Officer.
• John F. Paolini, M.D. will serve as Senior Vice President and Chief Medical Officer.

Industry Context

Redomiciliation is a strategic move for companies to optimize their corporate structure, often for tax or regulatory reasons. This move allows Kiniksa to operate under the legal framework of the UK.

Comparison to Industry Standards

• The redomiciliation process is similar to other companies that have moved their incorporation to different jurisdictions for strategic reasons.
• The one-for-one share conversion is a standard practice in such transactions, ensuring shareholders maintain their proportional ownership.
• The use of Depositary Receipts is a common mechanism to handle transfer restrictions and facilitate trading on exchanges like Nasdaq.

Corporate Governance

Stakeholder Impact

• Shareholders of Kiniksa Bermuda received equivalent shares in Kiniksa Pharmaceuticals International, plc, maintaining their ownership.
• Employees of Kiniksa Bermuda transitioned to Kiniksa Pharmaceuticals International, plc with the same roles and responsibilities.
• The company's operations will continue under the new corporate structure in the UK.

Next Steps

• The company will continue to operate under the new corporate structure in the UK.
• Holders of Depositary Receipts may request cancellation to effectuate a transfer of the underlying ordinary shares to Cede & Co.

Key Dates

Keywords

redomiciliation, Kiniksa Pharmaceuticals, successor issuer, Nasdaq, Depositary Receipts, share conversion, equity incentive plans, corporate structure